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Abstract
The dapE-encoded N-succinyl-l,l-diaminopimelic acid desuccinylase (DapE) is a critical bacterial enzyme for the
construction of the bacterial cell wall. A screen biased toward compounds containing zinc-binding groups (ZBG’s)
including thiols, carboxylic acids, boronic acids, phosphonates and hydroxamates has delivered a number of

micromolar inhibitors of DapE from Haemophilus influenzae, including the low micromolar inhibitor l-captopril
(IC50 = 3.3 μM, Ki = 1.8 μM). In vitro antimicrobial activity was demonstrated for l-captopril against Escherichia
coli.

Graphical abstract
A screen biased toward compounds containing zinc-binding groups (ZBG’s) delivered a number of micromolar
inhibitors of DapE from Haemophilus influenzae, including l-captopril (IC50 = 3.3 μM, Ki = 1.8 μM). In vitro
antimicrobial activity was demonstrated for l-captopril against Escherichia coli.
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Article
Bacterial infections are a significant and growing medical problem in both the United States and around the
world.1 The CDC recently reported that there are now several strains of Staphylococcus aureus that are resistant
to all known antibiotics including vancomycin.2 These cases underscore the fact that limited numbers of drugs
are available to prevent a simple Staph infections from becoming deadly.3 At least four other strains of common
bacterial species capable of causing life-threatening illnesses (Enterococcus faecalis, Mycobacterium
tuberculosis, Escherichia coli O157:H7, and Pseudomonas aeruginosa) are already resistant to nearly all drugs in
clinicians, arsenal comprised of more than 100 drugs.4, 5 Thus, the search for new antibiotics that target
enzymes in unexplored bacterial biosynthetic pathways is critically important, as confirmed in Supuran’s
excellent review of bacterial protease inhibitors.6
The dapE-encoded N-succinyl-l,l-diaminopimelic acid desuccinylase (DapE) enzyme is a member of the mesodiaminopimelate (mDAP)/lysine biosynthetic pathway.7 The amino acids mDAP and/or lysine are essential
components of the peptidoglycan cell wall for Gram-negative and most Gram-positive bacteria, providing a link
between polysaccharide strands.7 Therefore, enzymes involved in the mDAP/lysine biosynthetic pathway,
including DapE, are potential antibiotic targets.
DapE’s are small, dimeric enzymes (41.6 kDa/subunit) that require two Zn(II) ions per mole of polypeptide for
full enzymatic activity.8, 9 On the basis of sequence alignments with other aminopeptidases10 and several DapE
gene sequences, all of the residues that function as ligands in the dinuclear active site of those enzymes are
strictly conserved in DapE from Haemophilus influenzae. Studies on the E134A- and E134D-altered DapE
revealed that E134 acts as the general acid/base in the hydrolysis of the substrate and is absolutely required for
catalytic activity.11 Investigations on H67A- and H349A-altered enzymes together with construction of a threedimensional homology structure of DapE from Haemophilus influenzae (generated using the X-ray crystal
structure of the Apo-DapE from Neisseria meningitidis as a template with superposition on the structure of the

aminopeptidase from Aeromonas proteolytica (AAP)) confirmed the identification of active site histidine zinc
ligands.12 Based on this homology model, the active site of DapE contains two Zn(II) ions at a distance of
∼3.30 Å (Fig. 1).

Figure 1. Proposed active site of DapE enzymes.
Each of the Zn(II) ions adopts a distorted tetrahedral geometry and is coordinated by one imidazole group (H67
for Zn1 and H349 for Zn2) and one carboxylate group (E163 for Zn1 and E135 for Zn2). Both Zn(II) ions are
bridged by an additional carboxylate groups (D100) on one side and water/hydroxide on the opposite side,
forming a (μ-aquo)(μ-carboxylato)dizinc(II) core with one terminal carboxylate and one histidine residue at each
metal site.
In order to identify appropriate lead molecules for the inhibition of DapE, we have screened13 over thirty
molecules representing various structural classes and containing different zinc-binding groups (ZBG’s) using Nsuccinyl l,l-diaminopimelic acid (l,l-SDAP) as the substrate.14 These ZBG’s include thiols, hydroxamates, carboxylic
acids, boronic acids, and phosphates, and this fruitful initial screen has led to the identification of a number of
low micromolar inhibitors (Table 1). We biased our initial screen to include bifunctional molecules that
contained, in addition to the ZBG, a carboxylate moiety that could interact with the positively-charged lysine
and/or arginine side chains that purportedly reside near the active site. Table 1 shows carboxylic acid-containing
thiols that were found to inhibit DapE fairly potently. Even delta-mercaptobutyric acid has an IC50 of 43 μM
versus DapE, and meta-mercaptobenzoic acid has a measured IC50 of 34 μM. l-Penicillamine gave an IC50 of
13.7 μM, and a measured Ki of 4.6 μM. DapE is stereoselective with respect to recognition of inhibitors, as dpenicillamine gave an IC50 of 50 μM. Given the success with these carboxylic acid-containing thiols, we turned
our attention to captopril, which contains the requisite ZBG and carboxylate functionalities. l-Captopril exhibited
an IC50 of 3.3 μM and a measured Ki of 1.8 μM (competitive). Again, the binding is stereoselective, as dcaptopril15 was an order of magnitude less potent, with an IC50 of 42.0 μM.
Table 1. Thiols tested as inhibitors of DapE
Compound
Structure
delta-Mercapto-butyric acid

43 ± 4

IC50 (μM)a

3-Mercapto-benzoic acid

34

l-Penicillamine

13.7
Ki = 4.6 ± 0.6 μM (competitive)

d-Penicillamine

50

l-Captopril

3.3
Ki = 1.82 ± 0.09 μM (competitive)

d-Captopril

42.0 ± 2.5

a. Values are means of three experiments.
Table 2 shows boronic acid derivatives that were tested as inhibitors of DapE. Phenylboronic acid itself was
encouraging with an IC50 of 107 μM and a measured Ki of 56.9 μM (competitive). Incorporation of a carboxylic
acid along with the boronic acid was not productive, as both 4-carboxyphenylboronic acid and 3carboxyphenylboronic acid did not inhibit DapE. It is hypothesized that geometric constraints may have
precluded a productive Coulombic interaction of the carboxylate with positively-charged residues in the active
site. Butylboronic acid was a weak inhibitor of DapE (IC50 ∼10 mM). 2-Thiopheneboronic acid was comparable to
phenylboronic acid, with an IC50 of 92 μM and a measured Ki of 67 μM, but the inhibitor was noncompetitive.
Surprisingly, 1-butaneboronic is only a very weak inhibitor of DapE (IC50 ∼ 10,000 μM) even though it is a potent
inhibitor of AAP (Ki = 10 μM).16, 17
Table 2. Boronic acid tested as inhibitors of DapE
Compound
Structure
Phenylboronic acid

IC50 (μM)a

4-Carboxyphenyl-boronic acid

107
Ki = 56.9 ± 3.6 μM (competitive)
>10,000

3-Carboxyphenyl-boronic acid

>10,000

Butylboronic acid

−10,000

2-Thiopheneboronic acid

92
Ki = 67 ± 3.8 μM (non-competitive)

a. Values are means of three experiments.
Table 3 shows several other compounds that were screened versus the DapE enzyme. Given the very good
potency of the ACE inhibitor l-captopril noted above (IC50 = 3.3 μM), the ACE inhibitor enalapril was screened,
but did not show any potency versus DapE. Two simple hydroxamate compounds, acetohydroxamic acid and N(benzyloxycarbonyl)hydroxylamine (actually an N-hydroxy carbamate) were also screened but were too weak to
measure the inhibitory potency. N-Phenylthiourea could potentially function as a zinc-binding compound and
showed some inhibition of DapE, but the IC50 is greater than 100 μM. Phosphonic acids can also inhibit
metalloproteases, and (2-carboxyethyl)phosphonic acid was shown to have a very weak IC50 of 1620 μM.
Table 3. Other potential inhibitors explored as potential inhibitors of the DapE enzyme
Compound
Structure
IC50 (μM)a
Enalapril (maleate salt)
>1000

Aceto-hydroxamic acid

>1000

N-(Benzyloxy-carbonyl)hydro xylamine

>1000

N-Phenyl-thiourea

>100

(2-Carboxyethyl)-phosphonic acid

1620
Ki = 800

a. Values are means of three experiments.
Several alkyl and aryl phosphates have also been tested in addition to diaminopimelic acid amides and ornithine
amides (structures not shown). In all cases, these molecules exhibited little or no inhibitory potency (IC50
>1000 μM to >10,000 μM). Finally, (d,l)-(2-phosphonomethyl)-pentanedioic acid did not inhibit DapE at
concentrations up to 10 mM. 2-Carboxyethyl phosphonic acid is a significantly better inhibitor (Ki = 800 μM) than
phosphonoacetic acid, 3-phospho-propanoic acid, or N-(phosphonomethyl)glycine, thus presenting an optimal
chain length for interactions with DapE. We expect an optimal distance between thiol and carboxylate in the
thiol series as well, depending on conformational mobility of the series.
We have confirmed antibiotic activity with the DapE inhibitor, l-captopril, in an antibiotic plate assay as
illustrated in the following photos (Fig. 2). Application of l-captopril directly to plates cultured with Escherichia
coli showed a dose–responsive antibiotic activity for this DapE inhibitor. Very little inhibition is observed for
1 mg of l-captopril, but 5 mg demonstrates a clear positive antibiotic result, and the zone of inhibition is even
greater for 20 mg of l-captopril. Furthermore, this confirms that the enzyme inhibitor is crossing the bacterial
cell membrane and reaching the desired target. The positive antibiotic control ampicillin is shown as well
showing its zone of inhibition.

Figure 2. Antibiotic activity of l-captopril against E. coli.
In summary, a screen of compounds containing ZBG’s against DapE from Haemophilus influenzae has delivered a
number of micromolar inhibitors including captopril, functioning as a competitive, reversible inhibitor with an
IC50 of 3.3 μM (Ki = 1.8 μM). Furthermore, antibiotic activity has now been demonstrated for the DapE inhibitor lcaptopril. Captopril is an excellent lead for medicinal chemistry optimization in consideration of its low
molecular weight (217) and low measured log P of 0.3418, 19 following the rules of Lipinski20 and containing few
rotatable bonds,21 consistent with its known oral bioavailability.
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Materials. D,L-α,ε-DAP (98% pure), succinic anhydride and ion exchange resin (Dowex 50WX8-200, H form)
were purchased from Sigma, 2-naphthalenesulfonic acid 99% was from Acros Organics. Cellulose for column
chromatography was purchased from Fluka. L-penicillamine, D-penicillamine, 4-mercaptobutyric acid were
purchased from Chem-Impex International, (Wood Dale, IL)and L-captopril from MP Biomedicals Inc. (Solon,
OH). D-Captopril was prepared according to the method of Smith.{{1595 Smith,Elizabeth M. 1988; }} All other
chemicals used in this study were purchased from Sigma and were of the highest quality available.
Synthesis of N-succinyl-diaminopimelic acid (L,L-SDAP). The D,D- and L,L-isoforms of DAP were separated from
the D,L- isoform using the method described by Bergmann and Stein (16). SDAP was synthesized using the
procedure described by Lin et al. (17) providing an overall yield of 41% (1.84g; 5.7mmol). NMR (D2O, 270MHz),
δ (ppm) 1.25-1.45 (m, 2H), 1.55-1.90 (m, 4H), 2.29-2.52 (m, 4H), 3.64 (dd, 1H), 4.05 (dd, 1H), 4.76 (bs, H2O +
ammonium ion). The L,L- and D,D- SDAP isoforms were separated using an HPLC (Shimadzu SCL-10A VP) with a
Chirobiotic T column (250 x 10 mm; Alltec). The isocratic mixture of 20% methanol in water (adjusted to pH 4)
was used as the eluting solvent. The two isoforms were present in an approximate 1:1 ratio.
Protein Expression and Purification. The recombinant DapE from H. influenzae was expressed and purified, as
previously described (Timothy L. Born, Renjian Zheng, and John S. Blanchard (1998) Biochemistry
37:10478–10487) with minor modifications, from a stock culture kindly provided by Professor John Blanchard.
Briefly, ~12 grams of cell paste were suspended in 50 mL of 10 mM Tricine buffer, pH 7.8, containing one
protease inhibitor tablet (complete protease inhibitor cocktail tablets, EDTA-free, Roche Diagnostic GmbH,
Mannheim, Germany). Lysozyme (10 mg) was added to the mixture and stirred for 30 minutes at 4 °C. Cells
were lysed by sonication (Sonicator 3000, Misonix, Farmingdale, NY) at 30s intervals, eight repetitions (27W),
with 45s break after each sonication. The cell debris was removed by centrifugation for 40 minutes at 12,000 G.
DNase (2 mg) was added and after ~20 min. of incubation it was spun again for 15 min. at 18000 RPM. The
solution was loaded onto a fast-flow Q-sepharose anion exchange column (XK50, GE Healthcare, Amersham
Biosciences Corp., Piscataway, NJ, USA) that had been pre-equilibrated with 10 mM Tricine, pH 7.8. A flow rate
of 3 mL per minute was used and a 600-minute linear gradient of NaCl (0.2 to 0.5 M) was used to elute DapE.
DapE activity was detected between 0.25 and 0.4 M NaCl. The active fractions were concentrated using an
Amicon YM-10 membrane. Purified DapE from H. influenzae exhibited a single band on SDS-PAGE indicating Mr
= 41,500. Protein concentrations were determined from the absorbance at 280 nm using a molar absorptivity
calculated using the method developed by Gill and Hippel (Gill, Stanley C.; Von Hippel, Peter H. (1989)
Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 182:319–326 ) (ε280
= 36,040 M-1 cm-1). The protein concentration determined using this molar absorptivity was in close agreement
to that obtained using a Bradford assay. Individual aliquots of purified DapE were stored in liquid nitrogen until
needed.

Metal removal from altered DapE enzymes. Apo-DapE enzyme was prepared by extensive dialysis for 3 to 4 days
against 10 mM EDTA in 50 mM HEPES, pH 7.5. DapE enzyme was then exhaustively dialyzed against metal-free
(Chelex-100 treated) 50 mM HEPES, pH 7.5. The presence of any remaining metal ions in solution or bound by
DapE were estimated by comparing the activity of the apo-enzyme with a sample that had been reconstituted
with Zn(II). DapE enzyme samples incubated with EDTA typically had less than 5% residual activity after dialysis.
Enzymatic assay of DapE. The specific activity, Vmax (velocity) and Km (Michaelis constant) of the Zn
reconstituted DapE enzyme was determined in triplicate by monitoring amide bond cleavage of L,L-SDAP at 225
nm in Chelex-100 treated 50 mM potassium phosphate buffer, pH 7.5 (DD,LL-SDAP was used as a substrate;
ε225nm= 304 M-1 cm-1). Enzyme activities are expressed as units/mg where one unit is defined as the amount of
enzyme that cleaves 1 mol of substrate at 25 ˚C in 1 min. Catalytic activities were determined with an error of
± 10 %. Initial rates were fit directly to the Michaelis-Menten equation to obtain the catalytic constants
Km=1.75mM and Vmax=0,027mM/min.
Inhibition Studies. All experiments were performed in 50 mM chelexed potassium phosphate buffer pH 7.6.
3mM solution of DD,LL-SDAP in the same buffer was used for IC50 determination. Ki was determined using 0,54,5mM substrate concentrations and different inhibitor concentrations (depending on the inhibitor). Total
volume of the mixture was 1ml.
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